66th ASH Annual Meeting: 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I

Symposia: Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis Oral and Poster Abstracts
Poster

Research, Antibody Therapy, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, Combination therapy, AML, Fundamental Science, Adult, Bispecific Antibody Therapy, Translational Research, Epidemiology, CHIP, Assays, Elderly, Genomics, Bioinformatics, CML, Clinical Research, Health outcomes research, Chronic Myeloid Malignancies, Pediatric, Diseases, Immune mechanism, Patient-reported outcomes, Neonatal, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Real-world evidence, Lymphoid Malignancies, Registries, Young adult , Biological Processes, Myeloid Malignancies, Monoclonal Antibody Therapy, Technology and Procedures, Molecular biology, Study Population, Profiling, Human, Measurable Residual Disease , Machine learning, Molecular testing, Omics technologies

Halls G-H (San Diego Convention Center)

1451

Comprehensive Fusion Gene Landscape in B-Cell Lymphoblastic Leukemia: Insights from Transcriptome Sequencing of 1015 Cases

Xue Chen, MD¹^*, Lili Yuan, MD²^*, Xiaoli Ma, MD¹^*, Fang Wang, MD¹^*, Yang Zhang, MD¹^*, Panxiang Cao, MD²^*, Jiancheng Fang, MD³^*, Tong Wang, MD²^*, Jiaqi Chen, PhD²^*, Xiaosu Zhou, PhD⁴^* and Hongxing Liu, MD^2,5

¹Department of Clinical Laboratory, Hebei Yanda Lu Daopei Hospital, Langfang, China
²Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China
³Department of Clinical Laboratory, Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
⁴Precision Medicine Center, Beijing Lu Daopei Institute of Hematology, Beijing, AL, China
⁵Precision Medicine Center, Beijing Lu Daopei Institute of Hematology, Beijing, China

1452

Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia

Kathryn Kimi Shimamoto^1,2^*, Arda Arda Karaoglu^1,2^*, Zachary Chan³^*, Giorgia Giordano, BE⁴^*, Bartholomew Eisfelder, PhD⁴^*, Jason Xiaojun Cheng, MD, PhD⁵, Hamed Youshanlouei⁴^*, Syed Shah⁴^*, Anand Ashwin Patel, MD⁶, Adam S. Duvall, MD⁶, Francis Burrows, PhD⁷^*, Linda Kessler, BA⁷^*, Michael W Drazer, MD, PhD⁸, Olatoyosi Odenike, MD⁶, Michael J. Thirman, MD⁴, Wendy Stock, MD⁶ and Caner Saygin, MD⁶

¹Section of Hematology/Oncology, The University of Chicago, Chicago, IL, Chicago, IL
²Contributed equally, Chicago
³Cornell University, Ithaca
⁴Section of Hematology/Oncology, The University of Chicago, Chicago, IL, Chicago
⁵Department of Pathology, The University of Chicago, Chicago, IL, Chicago
⁶Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
⁷Kura Oncology, Carlsbad
⁸Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL

1453

Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Ryo Nakagawa^1,2^*, Yosuke Isobe³^*, Ari Itoh-Nakadai⁴^*, Haruki Uchino³^*, Minggao Liang⁵^*, Akiko Kaneko⁴^*, Kaori Sato⁴^*, Mariko Tomizawa-Murasawa⁴^*, Saera Fujiki⁴^*, Emi Kanamaru⁴^*, Hanae Amitani⁶^*, Mikiko Endo⁶^*, Shinsuke Takagi, MD, PhD⁷^*, Naoyuki Uchida⁷, Shuichi Taniguchi, MD⁷^*, Yukihide Momozawa⁶^*, Yoriko Saito⁴, Makoto Arita³^*, Hideo Harigae, MD, PhD¹ and Fumihiko Ishikawa⁴

¹Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan
²Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Kawasaki, KAN, Japan
³Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
⁴Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
⁵Laboratory for Applied Computational Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
⁶Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
⁷Department of Hematology, Toranomon Hospital, Tokyo, Japan

1454

The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT

Hermione E Allen¹^*, Andrew McIntyre, PhD²^*, Jesus Gutierrez-Abril, PhD³^*, Amy A Kirkwood, MSc⁴^*, Daniel Leongamornlert, PhD⁵^*, Rodothea Amerikanou, MBBChir¹^*, Emily A Cutler, MSc¹^*, Aditi Dey, PhD¹^*, Richard Burt, PhD, FRCPath, MRCP^6,7^*, Ronjon Chakraverty²^* and Adele Kay Fielding, MBBS, PhD^1,8

¹Cancer Institute, University College London, London, United Kingdom
²Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
³Memorial Sloan Kettering Cancer Centre, New York City
⁴Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom
⁵Cancer, Ageing and Somatic Mutation (CASM), Wellcome Sanger Institute, Hinxton, United Kingdom
⁶Imperial College London, London, United Kingdom
⁷The Francis Crick Institute, London, United Kingdom
⁸Hull York Medical School, University of York, York, United Kingdom

1455

KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Venkata Sesha Sai Abhinav Ayyadevara, PhD, MS¹^*, Gerald Wertheim, MD, PhD²^*, John Chukinas³^*, Joseph Loftus³^*, Sung June Lee⁴^*, Anil Kumar, PhD⁵^*, Srividya Swaminathan, PhD⁶, Rahul S Bhansali, MD⁷, Wayne Childers⁸^*, Huimin Geng, PhD⁹^*, Thomas A Milne¹⁰, Xianxin Hua, MD, PhD¹¹^*, Kathrin M. Bernt, MD³, Thierry Besson¹²^*, Junwei Shi, PhD¹³^*, John D. Crispino, PhD¹⁴, Martin P Carroll, MD², Sarah K Tasian, MD¹⁵ and Christian Hurtz, PhD¹⁶

¹Division of Cancer Sciences, Loma Linda University, Philadelphia, PA
²Division of Hematology/Oncology, Department of Medicine, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA
³Children's Hospital of Philadelphia, Philadelphia, PA
⁴City of Hope Beckman Research Institute, Duarte, CA
⁵City of Hope, Duarte, CA
⁶City of Hope - BRC, Duarte, CA
⁷Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁸Temple University, Philadelphia, PA
⁹Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
¹⁰Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
¹¹University of Pennsylvania, Philadelphia, PA
¹²Normandie University, Rouen, FRA
¹³Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
¹⁴Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN
¹⁵Division of Oncology & Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
¹⁶Division of Cancer Sciences, Loma Linda University, Loma Linda, CA

1456

Ting Zhou, MD, PhD¹^*, Nicholas J. Short, MD², Nitin Jain, MD², Keyur P. Patel, MD, PhD³^*, Elias Jabbour, MD², Hagop M. Kantarjian, MD², L. Jeffrey Medeiros, MD³ and Bryan Iorgulescu, MD, MPH, FCAP⁴^*

¹Memorial Sloan Kettering Cancer Center, New York
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Molecular Diagnostics Laboratory, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

1457

Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1^plusgenotyping and MRD Assessment in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia

Cheng Wang, MAS¹^*, Jianfeng Li, PhD²^*, Weiyang Liu, MD³^*, Han Yan²^*, Yuchen Yan²^*, Lingling Zhao²^*, Jiayi Ren, MD²^*, Lijun Peng²^*, Jiaojiao Zhang²^*, Yuanfang Liu, MD, PhD²^*, Xiangqin Weng, Master²^*, Yongmei Zhu, PhD²^*, Weiping Zhang, MD, PhD²^*, Jie Xu, MD, PhD², Duohui Jing²^*, Jian-Qing Mi²^* and Jin Wang, MD, PhD²^*

¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, TX, China
²Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
³Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, AL, China

1458

C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL

Björn-Thore Hansen^1,2,3^*, Thomas Beder^2,3,4^*, Sören Döhle²^*, Wencke Walter, PhD⁵, Malwine J Barz, PhD^2,3,4^*, Cecilia Bozzetti, MD²^*, Johanna Horns^2,3^*, Axel Künstner^6,7^*, Alina M. Hartmann^3,4,8^*, Sören Franzenburg⁹^*, Michael Wittig¹⁰^*, Barbara Ritter¹¹^*, Stefan Schwartz, MD¹²^*, Hauke Busch, PhD^6,13^*, Nikos Darzentas, PhD^3,14^*, Claudia Haferlach, MD¹⁵, Nicola Goekbuget, MD¹⁶, Monika Brüggemann, MD^3,4,14^*, Claudia D Baldus, MD^3,4,14^* and Lorenz Bastian^2,3,4^*

¹(DFG, German Research Foundation): 413490537, Clinician Scientist Program in Evolutionary Medicine funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
²Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
³University Medical Center Schleswig-Holstein, University Cancer Center Schleswig-Holstein, Kiel, Germany
⁴Clinical Research Unit CATCH ALL (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
⁵Munich Leukemia Laboratory, Munich, Germany
⁶Medical Systems Biology Group, University of Lübeck, Lübeck, Germany
⁷University Medical Center Schleswig-Holstein, University Cancer Center Schleswig-Holstein, Lübeck, Germany
⁸Department of Internal Medicine II (Hematology/Oncology), University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
⁹Institute for Clinical Molecular Biology, Kiel University, Kiel, DEU
¹⁰Institute for Clinical Molecular Biology, Kiel University, Kiel, Germany
¹¹Department of Hematology, Oncology and Immunology, Klinikum Kassel, Kassel, Germany
¹²Department of Hematology, Oncology and Cancer Immunology (Campus Benjamin Franklin), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany
¹³University Cancer Center Schleswig-Holstein, Lübeck, Germany
¹⁴Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany
¹⁵MLL Munich Leukemia Laboratory, Munich, Germany
¹⁶Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany

1459

Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia

Judith M. Boer, PhD¹, Marco J. Koudijs, PhD²^*, Lennart A. Kester, PhD²^*, Edwin Sonneveld, PhD²^*, Jayne Y. Hehir-Kwa, PhD¹^*, Simone Snijder, PhD³^*, Esmé Waanders, PhD³^*, Arjan Buijs, PhD⁴^*, Valerie de Haas, PhD, MD¹^*, Inge M. van der Sluis, MD, PhD¹, Rob Pieters, MD, PhD¹, Monique L. den Boer, PhD¹ and Bastiaan B.J. Tops¹^*

¹Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
²Princess Maxima Center for pediatric oncology, Utrecht, Netherlands
³Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands
⁴Genome Diagnostics, University Medical Center Groningen, Groningen, Netherlands

1460

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Stefan Habringer^1,2^*, Iva Todorova²^*, Frederik Herzberg, MD²^*, Daniel Steiert²^*, Arik Horne, PhD³^*, Thomas Burmeister, MD, PhD⁴^*, Simon Haas, PhD³^*, Ulrich Keller^1,2,5^*, Monika Brüggemann, MD^6,7^*, Michaela Kotrova, MD, PhD^6,8^*, Claudia D Baldus, MD^6,8^*, Nicola Goekbuget, MD^9,10, Martin Neumann, MD^6,8^* and Stefan Schwartz, MD^1,2^*

¹German Cancer Consortium (DKTK) partner site Berlin, a partnership between DKFZ and Charité – Universitätsmedizin Berlin, Berlin, Germany
²Department of Hematology, Oncology and Cancer Immunology (Campus Benjamin Franklin), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany
³Berlin Institute of Health (BIH), Berlin, Germany
⁴Department of Hematology, Oncology and Cancer Immunology (Campus Virchow Klinikum), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany
⁵Max-Delbrück-Center, Berlin, Germany
⁶University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany
⁷Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany
⁸Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
⁹Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt/Main, Germany
¹⁰German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, a partnership between DKFZ and Goethe University, Frankfurt/Main, Germany

1461

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens

Jayastu Senapati, MD, DM, MBBS¹, Hagop M. Kantarjian, MD¹, Clark Robinson, MD²^*, Koichi Takahashi, MD, PhD³, Nitin Jain, MD¹, Fadi G. Haddad, MD¹, Courtney D. DiNardo, MD, MSc⁴, Sanam Loghavi, MD⁵, Guilin Tang, MD, PhD⁵^*, Guillermo Montalban-Bravo, MD¹, Tapan M. Kadia, MD¹, Naval Daver, MD⁶, Koji Sasaki, MD¹, Zena Komrokji⁷^*, Rebecca Garris¹^*, Guillermo Garcia-Manero, MD¹, Farhad Ravandi, MBBS⁸, Nicholas J. Short, MD¹ and Elias Jabbour, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, MD Anderson, Saint Paul, MN
³Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁵Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶MD Anderson Cancer Center, Houston, TX
⁷Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁸Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

1462

Chromothripsis Is Enriched at Relapse of Childhood B-Cell Precursor Acute Lymphoblastic Leukemia and Cooccurs with Loss of Function of TP53 and RB1 Genes

Zuzanna Urbanska^1,2^*, Karolina Miarka-Walczyk, M.Sc.¹^*, Kamila Wypyszczak, M.Sc.¹^*, Borys Styka, M.Sc.³^*, Monika Lejman, Ph.D.³^*, Kinga Ostrowska, Ph.D.²^*, Joanna Taha, Ph.D.²^*, Zuzanna Nowicka, M.D.⁴^*, Klaudia Starosz¹^*, Bartosz Urbanski, M.D.²^*, Katarzyna Adamczewska-Wawrzynowicz, M.D., Ph.D.⁵^*, Katarzyna Derwich, Prof., M.D., Ph.D.⁵^*, Wojciech Fendler⁴^*, Monika Mielcarek-Siedziuk, M.D., Ph.D.⁶^*, Tomasz Szczepanski, Prof., M.D., Ph.D.⁷, Wojciech Mlynarski, Prof., M.D., Ph.D.²^* and Agata Pastorczak, M.D., Ph.D.^1,2^*

¹Department of Genetic Predisposition to Cancer, Medical University of Lodz, Lodz, Poland
²Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland
³Laboratory of Genetic Diagnostics, Medical University of Lublin, Lublin, Poland
⁴Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland
⁵Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland
⁶Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland
⁷Department of Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze, Poland

1463

Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development

Heye Yu¹^*, Wenbing Liu²^*, Junping Zhang¹^*, Leling Xie¹^*, Anli Lai¹^*, Zheng Tian¹^*, Kejing Tang¹^*, Haiyan Xing¹^*, Wang Ying, M.D.¹^*, Hui Wei, MD³^*, Qing Rao¹^*, Runxia Gu, MD¹^*, Min Wang¹^*, Huijun Wang³^*, Jianxiang Wang, MD¹ and Shaowei Qiu, MD¹^*

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Tianjin, China

1464

Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Jason Xu^1,2, Jonathan Sussman³^*, Austin Yang⁴^*, Satoshi Yoshimura, MD⁵^*, Changya Chen², Omar Elghawy, MD⁶^*, Tiffaney Vincent, BS⁷^*, Caroline Diorio, MD², Shovik Bandyopadyay⁴^*, Jianzhong Hu, BS⁸^*, Alexander Lai Li⁹^*, Gregory M. Chen, MD, PhD¹⁰^*, Chia-Hui Chen¹¹^*, Rawan Shraim, PhD²^*, Haley Newman, MD², Yang Ding¹¹, Elizabeth Li, MD¹²^*, Wenbao Yu¹¹^*, Anusha Thadi⁹^*, Kyung Jin Ahn⁴^*, Petri Pölönen, PhD¹³, Abdelrahman Elsayed⁸^*, David Frank, MD, PhD¹⁴^*, Elizabeth A. Raetz, MD¹⁵, Mignon L. Loh, MD¹⁶, Brent L. Wood, MD, PhD¹⁷, Stuart S. Winter, MD¹⁸, Kimberly P. Dunsmore, MD¹⁹^*, Meenakshi Devidas, PhD, MBA²⁰, Chunxu Qu¹³^*, Stanley Pounds, PhD²¹^*, Stephen P. Hunger, MD²², Charles G. Mullighan, MBBS, MSc, MD¹³, Jun J. Yang, PhD⁵, Kai Tan, PhD²³ and David T. Teachey, MD²⁴

¹Perelman School of Medicine, Philadelphia, PA
²Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
³Perelman School of Medicine, Philadelphia
⁴Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
⁵Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
⁶Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁷The Children's Hospital of Philadelphia, Philadelphia, PA
⁸St. Jude Children's Research Hospital, Memphis, TN
⁹Children's Hospital of Philadelphia, Philadelphia
¹⁰Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
¹¹Children's Hospital of Philadelphia, Philadelphia, PA
¹²Children’s Hospital of Philadelphia, Philadelphia, PA
¹³Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
¹⁴Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA
¹⁵Department of Pediatrics, NYU Langone Health, New York, NY
¹⁶Ben Towne Center for Childhood Cancer Research, Seattle Children’s Hospital, Fred Hutch Cancer Center, University of Washington, Seattle, WA
¹⁷Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA
¹⁸Cancer and Blood Disorders, Children's Minnesota, Eagan, MN
¹⁹University of Virginia Health Sciences Center, Charlottesville, VA
²⁰St Jude Children's Research Hospital, Memphis, TN
²¹Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
²²Division of Oncology, Childrens Hospital of Philadelphia, Philadelphia
²³Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
²⁴Division of Oncology, Children's Hospital of Philadelphia, Rutledge, PA

1465

Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia

Daniel Nguyen, MD, PhD¹, Elias Jabbour, MD², Nitin Jain, MD³, Omer Karrar⁴^*, Cedric Nasnas, MD³^*, Fadi G. Haddad, MD³, Jayastu Senapati, MD, DM, MBBS³, Tapan M. Kadia, MD³, Rebecca Garris³^*, Hagop M. Kantarjian, MD¹ and Nicholas J. Short, MD³

¹University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, University of Texas M.D. Anderson Cancer Ctr., Houston, TX
³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴The University of Texas MD Anderson Cancer Center, Houston, TX

1466

Molecular Classification and Clinical Correlation Utilizing Next-Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia

Sudeepthi Bandikatla, MBBS, Moazzam Shahzad, MD, Bijal D Shah, MD and Todd C Knepper, PharmD^*

H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

1467

Recurrent Focal Mkks-SLX4IP Deletion in ETV6::RUNX1 and Ph/Ph-like B-ALL

Yang Zhang, MD^1,2^*, Ming Liu, MD¹^*, Xiaoli Ma, MD¹^*, Jiancheng Fang, MD¹^*, Fang Wang, MD¹^*, Xue Chen, MD¹^* and Hongxing Liu, MD^1,2

¹Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China
²Precision Medicine Center, Beijing Lu Daopei Institute of Hematology, Beijing, China

1468

Measurable Residual Disease in Adult B Lymphoblastic Leukemia: A Study of Concordance between Multiparametric Flow Cytometry, Next-Generation Sequencing of Immunoglobulin Gene Rearrangements, and Quantitative PCR

Jin Jung, PhD^1,2^*, Jae-Ho Yoon, MD, PhD³, Seok Lee, MD³, Ari Ahn, MD²^*, Jong-Mi Lee, MD^1,2^*, Yonggoo Kim, MD^1,2^* and Myungshin Kim, MD^1,2^*

¹Catholic Genetic Laboratory Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
²Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
³Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

614.P1.52 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I